Financing round led by Forbion with participation from BioMedPartners and founding investor BioGeneration Ventures Leiden, The Netherlands, February 6th, 2020 – Azafaros B.V. announced today the successful closing of its Series A financing round raising EUR 25 million...
ion of existing deal with leading Chinese ADC developer Total of six partnered ADCs based on Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies now under development AMSTERDAM, NETHERLANDS – January 7, 2020 – Synaffix B.V., a biotechnology company...
Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will...
Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBodyTM patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan...
NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with...
Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology...
